Glycopyrronium Bromide: Clinical Trials

11 trials of Glycopyrronium Bromide, newest first

ClinicalTrials Daily · Areas · Conditions · Drugs · Sponsors ·

11 completed. 4 Phase 3, 3 Phase 2, 3 Phase 4, 2 Phase 1.

By phase and status

Phase	Trials	Status
Phase 3	4	Completed 4
Phase 2	3	Completed 3
Phase 4	3	Completed 3
Phase 1	2	Completed 2

Follow Glycopyrronium Bromide: new trials by email Literature Review of Glycopyrronium Bromide trials Research Report on Glycopyrronium Bromide

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
A Thorough QT (TQT) Study of CHF5993 pMDI in Healthy Volunteers (HV) CHF5993, CHF5259, Moxifloxacin 400mg - Asthma, Chronic Obstructive Pulmonary Disease (COPD)	Phase 1	Completed	Chiesi Farmaceutici S.p.A.	95	2023-03-29	2024-09-04
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD Beclomethasone Dipropionate, Glycopyrronium Bromide, Formoterol Fumarate - COPD, COPD Exacerbation	Phase 3	Completed	Chiesi Farmaceutici S.p.A.	3406	2022-04-27	2026-09-21
Effect of Glycopyrrolate on Vasopressors Requirement for Non-elective Caesarean Section Under Spinal Anaesthesia Glycopyrrolate 0.2 MG/ML, Normal saline - Glycopyrrolate, Post-spinal Hypotension	Phase 4	Completed	Rajesh Deshar	258	2020-06-01	2021-02-21
Clozapine-induced Hypersalivation - Feasibility Trial Hyoscine, Glycopyrrolate, Placebo - Sialorrhea	Phase 1 / Phase 2	Completed	Mersey Care NHS Trust	29	2016-01-25	2018-02-28
Acute Effect of Aclidinium on Hyperinflation and Ventilation Inhomogeneity in Severe COPD Patients Aclidinium Bromide, Glycopyrronium Bromide - Chronic Obstructive Pulmonary Disease	Phase 4	Completed	University of Milan	37	2014-06-01	2014-10-29
Study to Evaluate the Efficacy and Safety of Glycopyrronium or Indacaterol Maleate and Glycopyrronium Bromide Fixed-dose Combination Regarding Symptoms and Health Status in Patients With Moderate COPD Switching From Treatment With Any Standard COPD Regimen Glycopyrronium, SABA, LABA - COPD	Phase 4	Completed	Novartis Pharmaceuticals	4389	2014-02-14	2019-03-19
Dose Ranging Study of Glycopyrronium Bromide in Patients With Moderate or Severe Chronic Obstructive Pulmonary Disease glycopyrronium bromide - Chronic Obstructive Pulmonary Disease	Phase 2	Completed	Prosonix Limited	37	2013-05-01	2016-03-30
Efficacy, Safety and Tolerability of the Co-administration of NVA237 Plus Indacaterol Once Daily Versus Indacaterol Once Daily in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) NVA237 50 µg and indacaterol 150 µg, Placebo to NVA237 and indacaterol 150 µg - Chronic Obstructive Pulmonary Disease (COPD)	Phase 3	Completed	Novartis Pharmaceuticals	449	2012-05-01	2014-11-14
A Study to Assess the Safety, Tolerability and Efficacy of NVA237 Versus Placebo Glycopyrronium bromide, Placebo - Chronic Obstructive Pulmonary Disease	Phase 3	Completed	Novartis	1324	2009-10-01	2012-04-12
1-year Study to Assess the Efficacy, Safety, and Tolerability of Glycopyrronium Bromide (NVA237) in Chronic Obstructive Pulmonary Disease (COPD) Glycopyrronium bromide, Placebo to glycopyrronium bromide, Tiotropium - Chronic Obstructive Pulmonary Disease	Phase 3	Completed	Novartis	1066	2009-06-01	2012-08-17
Safety and Tolerability of 28 Days Treatment With Glycopyrronium Bromide (NVA237) (100 or 200 µg Once a Day) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease NVA237 100 µg, Placebo, NVA237 200 µg - Chronic Obstructive Pulmonary Disease (COPD)	Phase 2	Completed	Novartis	281	2007-08-01	2012-05-21

Conditions studied

Sponsors

Countries

Top investigators

Results publications

NIH funding